Latvija - latviešu - Zāļu valsts aģentūra

vip pharma eesti ou, estonia - glyceroli trinitras - tablete lietošanai zem mēles - 0,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - pentoksifilīns - Šķīdums injekcijām - 100 mg/5 ml

Latvija - latviešu - Zāļu valsts aģentūra

krka, d.d., novo mesto, slovenia - pentoksifilīns - ilgstošās darbības tablete - 400 mg

Latvija - latviešu - Zāļu valsts aģentūra

viatris healthcare limited, ireland - piridostigmīna bromīds - apvalkotā tablete - 60 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Latvija - latviešu - Zāļu valsts aģentūra

mylan ireland limited, ireland - piridostigmīna bromīds - ilgstošās darbības tablete - 180 mg

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

evolus pharma b.v. - botulīna toksīns, a tips - Ādas novecošanos - citi perifēriskas darbības miorelaksanti - pagaidu uzlabot izskatu, vidēji smagu vai smagu vertikālas līnijas starp uzacīm redzēt maksimālais skatiens (glabellar līnijas), kad smagumu virs sejas līnijas ir svarīga psiholoģiskā ietekme pieaugušajiem zem 65 gadu vecuma.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - sleep apnea, obstructive - other nervous system drugs - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing ltd - imidakloprīdu, moksidektīns - antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins - cats; dogs; ferrets - for cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of ear mite infestation (otodectes cynotis),• the treatment of notoedric mange (notoedres cati),• the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),• the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),• the treatment of the lungworm aelurostrongylus abstrusus (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme). Šīs veterinārās zāles var izmantot kā daļu no blusu alerģiskā dermatīta (fad) terapijas stratēģijas..  for ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis).  for dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of biting lice (trichodectes canis),• the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of circulating microfilariae (dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)• the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),• the reduction of circulating microfilariae (dirofilaria repens),• the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),• the treatment of angiostrongylus vasorum and crenosoma vulpis,• the prevention of spirocercosis (spirocerca lupi),• the treatment of eucoleus (syn. capillaria) boehmi (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis). Šīs veterinārās zāles var izmantot kā daļu no blusu alerģiskā dermatīta (fad) terapijas stratēģijas..

Latvija - latviešu - Zāļu valsts aģentūra

pro.med.cs praha a.s., czech republic - itoprīda hidrohlorīds - apvalkotā tablete - 50 mg